TABLE 2.
Vaccine coverage of invasive pneumococcal infections in different age groups
| Vaccine | No. (%) of covered clinical isolates from patients of age (yr):
|
||
|---|---|---|---|
| <5 (na = 69) | 5–64 (n = 129) | >64 (n = 49) | |
| 7-valent conjugate (formula B) | |||
| No cross-reactivity | 43 (62) | 53 (41) | 8 (16) |
| Serogroup cross-reactivity | 50 (72) | 68 (53) | 15 (31) |
| 9-valent conjugate | |||
| No cross-reactivity | 45 (65) | 55 (43) | 18 (37) |
| Serogroup cross-reactivity | 53 (76) | 73 (57) | 25 (51) |
| 11-valent conjugate | |||
| No cross-reactivity | 46 (67) | 72 (56) | 31 (63) |
| Serogroup cross-reactivity | 54 (78) | 91 (71) | 38 (78) |
| 23-valent polysaccharide | |||
| No cross-reactivity | 99 (77) | 31 (63) | |
| Serogroup cross-reactivity | 108 (84) | 38 (78) | |
a
n, total number of clinical isolates.